Diagnosis and Management of Cough: ACCP Evidence-Based Clinical Practice Guidelines

Richard S. Irwin; Michael H. Baumann; Donald C. Bolser; Louis-Philippe Boulet; Sidney S. Braman; Christopher E. Brightling; Kevin K. Brown; Brendan J. Canning; Anne B. Chang; Peter V. Dicpinigaitis; Ron Eccles; W. Brendle Glomb; Larry B. Goldstein; LeRoy M. Graham; Frederick E. Hargreave; Paul A. Kvale; Sandra Zelman Lewis; F. Dennis McCool; Douglas C. McCrory; Udaya B.S. Prakash; Melvin R. Pratter; Mark J. Rosen; Edward Schulman; John Jay Shannon; Carol Smith Hammond; Susan M. Tarlo

Diagnosis and Management of Cough: ACCP Evidence-Based Clinical Practice Guidelines
Richard S. Irwin

Introduction to the Diagnosis and Management of Cough: ACCP Evidence-Based Clinical Practice Guidelines
Richard S. Irwin

Methodology and Grading of the Evidence for the Diagnosis and Management of Cough: ACCP Evidence-Based Clinical Practice Guidelines
Douglas C. McCrory; Sandra Zelman Lewis

Anatomy and Neurophysiology of the Cough Reflex: ACCP Evidence-Based Clinical Practice Guidelines
Brendan J. Canning

Global Physiology and Pathophysiology of Cough: ACCP Evidence-Based Clinical Practice Guidelines
F. Dennis McCool

Complications of Cough: ACCP Evidence-Based Clinical Practice Guidelines
Richard S. Irwin

Overview of Common Causes of Chronic Cough: ACCP Evidence-Based Clinical Practice Guidelines
Melvin R. Pratter

Chronic Upper Airway Cough Syndrome Secondary to Rhinosinus Diseases (Previously Referred to as Postnasal Drip Syndrome): ACCP Evidence-Based Clinical Practice Guidelines
Melvin R. Pratter

Cough and the Common Cold: ACCP Evidence-Based Clinical Practice Guidelines
Melvin R. Pratter

Chronic Cough Due to Asthma: ACCP Evidence-Based Clinical Practice Guidelines
Peter V. Dicpinigaitis

Chronic Cough Due to Gastroesophageal Reflux Disease: ACCP Evidence-Based Clinical Practice Guidelines
Richard S. Irwin

Chronic Cough Due to Acute Bronchitis: ACCP Evidence-Based Clinical Practice Guidelines
Sidney S. Braman

Chronic Cough Due to Chronic Bronchitis: ACCP Evidence-Based Clinical Practice Guidelines
Sidney S. Braman

Chronic Cough Due to Nonasthmatic Eosinophilic Bronchitis: ACCP Evidence-Based Clinical Practice Guidelines
Christopher E. Brightling

Chronic Cough Due to Bronchiectasis: ACCP Evidence-Based Clinical Practice Guidelines
Mark J. Rosen
Through a comprehensive literature review, the evidence-based practice guidelines of the ACCP incorporate data from the most recent studies then available, which the ACCP views as being the best evidence available for the guideline’s general information purposes. Guidelines are not a substitute for the health-care provider’s own judgment for a specific medical or health condition. Patients should consult a qualified health-care professional for advice about a specific condition. Because of the ever-evolving field of medicine, new studies that may have become available late in the process of guideline development may not be incorporated into a particular guideline before it is disseminated. This prevents the ACCP from assuring the accuracy or completeness of a guideline. Therefore, the ACCP disclaims any liability to any party for the accuracy or completeness of a guideline or for any damages arising out of the use or non-use of its material and any information contained therein and all warranties, express or implied. Guideline users always are urged to seek out newer information that might impact the diagnostic and treatment recommendations contained within a guideline. Neither the ACCP nor third parties mentioned in a guideline are liable for any damages whatsoever (including, without limitation, direct, indirect, incidental, punitive, or consequential damages) arising out of the use, inability to use, or the results of use of a guideline, any references used in a guideline or the materials, information, or procedures contained in a guideline, whether based on warranty, contract, tort, or another legal theory and whether or not there was advice of the possibility of such damages.
# Panel List

**Diagnosis and Management of Cough: ACCP Evidence-Based Clinical Practice Guidelines**

Richard S. Irwin, MD, FCCP, Chair  
University of Massachusetts Medical School  
Worcester, MA

Michael H. Baumann, MD, FCCP (HSP Liaison)  
University of Mississippi Medical Center  
Jackson, MS

Donald Clementz Bolser, PhD  
University of Florida College of Veterinary Medicine  
Gainesville, FL

Louis Philippe Boulet, MD, FCCP  
(CTS Representative)  
Laval Hospital  
Sainte Foy, Canada

Sidney S. Braman, MD, FCCP  
Brown Medical School  
Providence, RI

Christopher E. Brightling, MBBS, FCCP  
Institute of Lung Health, Glenfield Hospital  
Leicester, United Kingdom

Kevin K. Brown, MD, FCCP  
National Jewish Medical & Research Center  
University of Colorado Health Sciences Center  
Denver, CO

Brendan J. Canning, PhD  
Johns Hopkins Asthma and Allergy Center  
Baltimore, MD

Anne B. Chang, MBBS, PhD  
Royal Children's Hospital  
Brisbane, Australia

Peter V. Diepinigaitis, MD, FCCP  
Einstein Division/Montefiore Medical Center  
Bronx, NY

Ron Eccles, DSc  
Cardiff School of Biosciences, Cardiff University  
Wales, United Kingdom

Wm Brendle Glomb, MD, FCCP  
Austin Children’s Chest Associates, P.A.  
Austin, Texas

Larry B. Goldstein, MD  
Duke University Medical Center  
Durham, NC

LeRoy M. Graham, MD, FCCP  
Georgia Pediatric Pulmonary Associates, PC  
Atlanta, GA

Frederick E. Hargreave, MD  
Firestone Institute for Respiratory Health  
Hamilton, Ontario, Canada

Paul A. Kvale, MD, FCCP  
Henry Ford Hospital  
Detroit, MI

Sandra Zelman Lewis, PhD  
American College of Chest Physicians  
Northbrook, IL

F. Dennis McCool, MD, FCCP  
Brown Medical School  
Providence, RI

Douglas McCrory, MD, MHSc  
Center For Clinical Health Policy Research  
Duke University Medical Center  
Durham, NC

Udaya B. S. Prakash, MD, FCCP  
Mayo Clinic  
Rochester, MN

Melvin R. Pratter, MD, FCCP  
Cooper University Hospital  
Robert Wood Johnson School of Medicine at Camden, NJ

Mark J. Rosen, MD, FCCP  
Beth Israel Medical Center  
New York, NY

Edward Schulman, MD, FCCP  
(ATS Representative)  
Hahnemann University Hospital  
Philadelphia, PA

John Jay Shannon, MD, FCCP  
(ACP Representative)  
Cook County Hospital  
Chicago, IL
Carol Smith Hammond, PhD
Duke University
Durham Veterans Administration Medical Center
Durham, NC 27705

Susan M. Tarlo, MBBS, FCCP
Toronto Western Hospital
Ontario, Canada
Disclosure of Faculty Conflict of Interest

Diagnosis and Management of Cough: ACCP Evidence-Based Clinical Practice Guidelines

The ACCP remains strongly committed to providing the best available evidence-based clinical practice guidelines with an open disclosure of any potential conflict of interest identified by our panelists. It is not the intent of the ACCP to eliminate all situations of potential conflict of interest, but rather to enable those who are working with the ACCP to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the guideline chair, the Health and Science Policy (HSP) Committee, or the Conflict of Interest Review Committee to ensure that such situations are properly evaluated and, if necessary, resolved. The ACCP standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all ACCP guideline development activities are ensured of independent, objective, scientifically balanced presentations of information.

The following panelists have indicated to the ACCP that no potential conflict of interest exists with any respective company/organization, and this is to be communicated to the readers of this guideline:

Dr. Irwin reveals no real or potential conflicts of interest or commitment.

Dr. Bolser reveals no real or potential conflicts of interest or commitment.

Dr. Canning reveals no real or potential conflicts of interest or commitment.

Professor Eccles reveals no real or potential conflicts of interest or commitment.

Dr. Glomb reveals no real or potential conflicts of interest or commitment.

Dr. Hargreave reveals no real or potential conflicts of interest or commitment.

Dr. Hammond reveals no real or potential conflicts of interest or commitment.

Dr. Kvale reveals no real or potential conflicts of interest or commitment.

Dr. Lewis reveals no real or potential conflicts of interest or commitment.

Dr. McCool reveals no real or potential conflicts of interest or commitment.

Dr. McCrory reveals no real or potential conflicts of interest or commitment.

Dr. Prakash reveals no real or potential conflicts of interest or commitment.

Dr. Shannon reveals no real or potential conflicts of interest or commitment.

The following panelists have disclosed to the ACCP that a relationship does exist with the identified companies/organizations, although these may not necessarily involve the topic of this guideline:

Dr. Baumann discloses that he is a shareholder of stock in Pfizer and Merck. He receives a consultant fee and serves on both speaker bureaus and advisory committees for Pfizer, Merck, Glaxo, and Boehringer.

Dr. Boulet discloses university grant monies from Altana Pharma research program in collaboration with the University Laval for $225,000 over 2 years. Other grant monies have been received from the Canadian Institute of Health research (CIHR), Institut de Recherche en Santé du Québec (IRSSST), Fonds de Recherche en Santé du Québec (FRSQ), Réseau en Santé Respiratoire (RSR-FRSQ), and Canadian Network of Centers of Excellence Allergen. Industry grants were received from 3M, AstraZeneca, Altana Pharma, Aventis, GlaxoSmithKline, Merck Frosst, Novartis, Schering, Genetech, Dynavax, and Roche. Dr. Boulet received consultant fees from AstraZeneca, Altana Pharma, Aventis, Boehringer-Ingelheim, GlaxoSmithKline, Merck Frosst, Novartis, Schering, Lung Associations, Canadian Provincial and Federal Governments and has served on advisory committees to AstraZeneca, Altana Pharma, GlaxoSmithKline, Merck Frosst, and Novartis.

Dr. Bragan discloses that he has received grant monies from AstraZeneca for clinical trials. He has received consultant fees and serves on both speaker bureaus and advisory committees for GlaxoSmithKline and Pfizer/Altana.

Dr. Brightling discloses grant income from MRC, Asthma UK, GSK, Schering-Plough, and CAT. He serves on a speaker bureau for AstraZeneca and GSK and has received consulting fees from AstraZeneca.

Dr. Brown discloses grant monies from NIH, NIEHS, NHLBI, Wyeth, Fibrogen, Genzyme, and Actelion and he has served on advisory committees for Wyeth, Fibrogen, Actelion, Encysive, Intermune, Genzyme, and Arizeke.

Dr. Chang discloses $2000 for an educational grant from Glaxo SKB.
Dr. Dicpinigaitis discloses consultant fees from Elan and Adams Respiratory Therapeutics, speaker bureau participation for Boehringer-Ingelheim and Pfizer, and membership in an advisory committee for Schering-Plough.

Dr. Goldstein has received research grants from NIH, Veterans Administration, CDC and UNC – Chapel Hill. He has served as the PI or on steering committees for clinical trials funded by Boehringer-Ingelheim, AGA Corp and Pfizer-Parke-Davis. Speaker honoraria were received from Bayer and Pfizer-Parke-Davis. Dr. Goldstein has participated in consultant or advisory boards for AstraZeneca, BMS/Sanofi, CuraGen Corp, DPharma, GlaxoSmithKline, Johnson & Johnson, Merck Research labs, Pfizer-Parke-Davis, and Proneuron Biotechnologies.

Dr. Graham has received grant monies from GlaxoSmithKline, AstraZeneca, and Sepracor. Consultant fees were paid to him by Merck and GlaxoSmithKline. He served on speaker bureaus for Merck, GlaxoSmithKline, AstraZeneca, and Sepracor and on advisory committees for Merck and GlaxoSmithKline.

Dr. Pratter received an unrestricted educational grant from Genentech and served on the speaker bureau for Boeringer-Ingelheim.

Dr. Rosen served on the speaker bureaus for Glaxo, Boehringer, Pfizer, and Schering.

Dr. Schulman has received grant monies from Boehringer-Ingelheim, Pfizer, Novartis, Genentech, CV Therapeutics, Sepracor, and GlaxoSmithKline. Consultant fees were received from Novartis and Genentech. Dr. Schulman serves on speaker bureaus for Merck, Novartis, and Genentech.

Dr. Tarlo has received consulting fees from Dow Chemical and Health Canada. She serves on an advisory committee for the Alberta University EPC for the AHRQ-funded review on occupational asthma.
List of Reviewers

Diagnosis and Management of Cough: ACCP Evidence-Based Clinical Practice Guidelines

ACCP Board of Regents
  COL Daniel R. Ouellette, MC, USA, FCCP
  LTC Lisa K. Moores, MC, USA, FCCP

Health and Science Policy
  Michael H. Baumann, MD, FCCP, Chair
  David D. Gutterman, MD, FCCP, Vice Chair
  Doreen J. Addrizzo-Harris, MD, FCCP
  Brian W. Carlin, MD, FCCP
  George L. Deelos, MD, FCCP
  Susan M. Harding, MD, FCCP
  Janet R. Maurer, MD, FCCP
  Atul C. Mehta, MBBS, FCCP
  COL John P. Mitchell, MC, USAF, FCCP
  Ian T. Nathanson, MD, FCCP
  Barbara A. Phillips, MD, FCCP
  Walter J. Scott, MD, FCCP
  Charlie Strange, MD, FCCP
  Pascal O. Udekwu, MBBS, FCCP

Airways Disorders NetWork
  Paula J. Anderson, MD, FCCP
  Claudia G. Cote, MD, FCCP
  Lourdes R. Laraya Cuasay, MD, FCCP
  Alan M. Fein, MD, FCCP
  Jill P. Karpel, MD, FCCP
  Frank T. Leone, MD, FCCP
  COL John P. Mitchell, MC, USAF, FCCP
  Jill A. Ohar, MD, FCCP
  Jay I. Peters, MD, FCCP
  E. Rand Sutherland, MD, FCCP

Clinical Pulmonary NetWork
  Nicola A. Hanania, MBBS, FCCP

  Rana B. Hejal, MD, FCCP
  Ayman O. Soubani, MBBS, FCCP

Occupational and Environmental Health Network
  Feroza M. Darowalla, MD, FCCP
  Clayton T. Cowl, MD, FCCP
  Dorsett Smith, DO, FCCP

Pediatric Chest Medicine NetWork
  C. Michael Bowman, MD, FCCP
  COL Edward B. Carter, MC, USA, FCCP
  COL Harlan S. Patterson, MC, USA, FCCP

Respiratory Care NetWork
  Russell A. Acevedo, MD, FCCP
  Michael G Ankin MD, FCCP
  Carl A. Kaplan, MD, FCCP
  Robert S. Pikarsky, RRT

Prior to submission for publication, the guideline review process of the ACCP is thorough and lengthy with multiple bodies charged with assessment including the Executive Committee of the panel, full guideline panel, Health and Science Policy Committee, appropriate NetWork(s) steering committee(s) members or designated reviewers, and the Executive Committee Board of Regents. This list of bodies included 39 individual reviewers whose exhaustive efforts helped to improve the resulting product. Although Dr. Irwin is the current Editor in Chief of CHEST as well as the chair of this guideline panel, the final manuscript, after review by the 39 individuals listed above, was submitted to CHEST in May 2005 and approved for publication by then Editor in Chief, Jay Block, MD, Master FCCP.